Lilly shared new Phase 3b findings involving its psoriasis drug Taltz together with Zepbound. The wire post gives few specifics.
Recap by typeshit. Post by @cgxpwire on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Late-stage trials show weight loss near 30%, with Phase 3 finishing in late 2026. Testing finds about 30% of gray-market peptide samples have problems.
A short local news segment checks the safety concerns around retatrutide, which is still in trials and not approved by the FDA.
Loading…